Michael J. Mitten - Concepedia

Author

Michael J. Mitten

Abbott Fund

Also Known As

M J Mitten, M Mitten, M. J. Mitten, M. Mitten, M.J. Mitten, Michael J Mitten, Michael J. Mitten, Michael Mitten

100

Publications

11.8K

Citations

H-Index

Concepts

All Affiliations

Abbott Fund AbbVie (United States)Abbott (United States)Walter and Eliza Hall Institute of Medical Research The University of Melbourne

About

Michael J. Mitten is an author at Abbott Fund specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	20	8.8K
2	Health Sciences	7	7	3.6K
3	Natural Sciences	5	5	208
4	Biochemistry	5	5	198
5	Cell Biology	5	5	4.5K

Michael J. Mitten

Publications

11.7K

Citations

H-Index

Page 1

	Year	Citations
An inhibitor of Bcl-2 family proteins induces regression of solid tumours Tilman Oltersdorf, Steven W. Elmore, Alexander R. Shoemaker, Nature Tumor BiologyBcl-2 Family ProteinsMedicineSolid TumoursCell Death	2005	3.4K
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets Andrew J. Souers, Erwin R. Boghaert, Scott Ackler, Nature Medicine ThrombopoiesisThrombosisHematological MalignancyOncologyAntitumor Activity	2013	2.9K
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor Christin Tse, Alexander R. Shoemaker, Jessica Adickes, Cancer Research	2008	1.9K
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy Darren C. Phillips, Michael J. Mitten, Erwin R. Boghaert, Science Translational Medicine Cancer TherapyChemoprevention StrategyBcl-2/bcl-xl/bcl-w Inhibitor Abt-263ImmunologyPharmacotherapy	2015	530
Discovery of a Potent and Selective BCL-X <sub>L</sub> Inhibitor with <i>in Vivo</i> Activity Zhi‐Fu Tao, Lisa Hasvold, Le Wang, ACS Medicinal Chemistry Letters	2014	328
Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models Elizabeth A. Punnoose, Franklin Peale, Erwin R. Boghaert, Molecular Cancer Therapeutics Hematological MalignancyTumor BiologyMedicineImmunologyPharmacology	2016	307
Studies Leading to Potent, Dual Inhibitors of Bcl-2 and Bcl-xL Milan Bruncko, Thorsten Oost, Barbara Belli, Journal of Medicinal Chemistry ImmunologyPharmacotherapyPharmaceutical ChemistryCompound 2Tumor Biology	2007	294
Potent and selective inhibitors of Akt kinases slow the progress of tumors <i>in vivo</i> Yan Luo, Alexander R. Shoemaker, Xuesong Liu, Molecular Cancer Therapeutics Akt KinasesSignal Transduction PathwaysMedicinePharmacologyTumor Growth Inhibition	2005	244
Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models Alex R. Shoemaker, Michael J. Mitten, Jessica Adickes, Clinical Cancer Research	2008	209
Souers AJ, Leverson JD, Boghaert ER et al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208 Andrew J. Souers, Erwin R. Boghaert, Scott Ackler, ThrombosisMolecular PharmacologyBlood PlateletNat MedMedicine	2013	182

Page 1